[go: up one dir, main page]

WO2022264097A1 - Composition pharmaceutique d'un agent anti-facteur de nécrose tumorale (anti-tnf) pour la gestion de maladies infectieuses provoquées par des coronavirus - Google Patents

Composition pharmaceutique d'un agent anti-facteur de nécrose tumorale (anti-tnf) pour la gestion de maladies infectieuses provoquées par des coronavirus Download PDF

Info

Publication number
WO2022264097A1
WO2022264097A1 PCT/IB2022/055626 IB2022055626W WO2022264097A1 WO 2022264097 A1 WO2022264097 A1 WO 2022264097A1 IB 2022055626 W IB2022055626 W IB 2022055626W WO 2022264097 A1 WO2022264097 A1 WO 2022264097A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
etanercept
administered
agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/055626
Other languages
English (en)
Inventor
Chirag Shah
Dhananjay BAKHLE
Kishore SONKUSARE
Kshipra GHARPURE
Preetam CHAVAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of WO2022264097A1 publication Critical patent/WO2022264097A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to pharmaceutical composition of anti-tumour necrosis factor (anti-TNF) agent for management of infectious diseases caused by coronavimses.
  • anti-TNF anti-tumour necrosis factor
  • the present invention provides a pharmaceutical composition or kit comprising etanercept which is an anti-TNF agent either alone or in combination with other therapeutic agents(s) for use in the management of COVID-19.
  • the invention also relates to their dosing regimens.
  • Coronavimses are large family of viruses that cause diseases like common cold, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
  • SARS Severe Acute Respiratory Syndrome
  • MERS Middle East Respiratory Syndrome
  • SARS-CoV-2 severe acute respiratory syndrome coronavims 2
  • COVID-19 coronavims disease 2019
  • Intensive research for vaccines and therapeutic agents for the prevention and treatment of COVID-19 is underway across the world.
  • One practical approach as a rapid response to an emerging pandemic is to repurpose existing therapeutic agents, since most of these agents have already been tested for their safety.
  • the present disclosure satisfies the need of re-purposing existing therapeutics in managing infection caused by coronavimses.
  • COVID-19 infection is accompanied by an aggressive inflammatory response with the release of a large amount of pro -inflammatory cytokines in an event known as “cytokine storm.”
  • Pro-inflammatory cytokines involved in COVID-19 are TNF- a, IL-6 and IL-1.
  • Pro-inflammatory cytokines are involved in the up-regulation of inflammatory reactions. Lung injury is one consequence of high levels of these cytokines, that can progress into more severe form like acute respiratory distress syndrome (ARDS).
  • ARDS is a type of respiratory failure characterized by low oxygen saturation levels, which is a major cause of mortality in COVID-19. Effectively suppressing the cytokine storm is an important way to prevent the deterioration of patients with COVID-19 infection and save the patients' lives.
  • TNF is by far the most well-characterized pro -inflammatory cytokine and it is also known to play a central role in other viral diseases, including those caused by influenza virus, dengue virus, and Ebola vims.
  • TNF-a was one of the cytokines whose overproduction was related to a poor prognosis in patients with SARS and MERS.
  • SARS-CoV-2 infection TNF-a levels increase early in the infection and remain elevated throughout the infection.
  • TNF-a in the lungs of COVID-19 patients induces HA-synthase-2 (HAS2) in EpCAM+ lung alveolar epithelium and CD31+ lung alveolar endothelium and fibroblasts.
  • HAS2 HA-synthase-2
  • HA hyaluronan
  • HA hyaluronan
  • TNFR1 primary receptor for TNF
  • anti- TNF therapies that block effects of TNF, presents a highly specific therapeutic approach to prevent cytokine storm or its complications.
  • TNF blockade leads to downregulation of pro-inflammatory mediators, including IF-1, IF-6, and granulocyte-macrophage colony stimulating factor within 24 hours.
  • Clotting biomarkers are also rapidly downregulated, with significant reductions in D-dimer and pro-thrombin fragments seen within 1 hour of anti-TNF therapy. Accordingly, therapeutics that can control the production of certain cytokines, especially TNF, may be useful in the management of diseases caused by coronavimses and hence, anti-TNF agents are potential treatment option that deserves high priority in the management of COVID-19.
  • Etanercept a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75-kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgGl, inhibits TNF-a, and to some extent TNF- b, by blocking its interaction with cell-surface TNF receptors, thereby modulating the biological responses induced or regulated by TNF.
  • TNFR tumor necrosis factor receptor
  • Etanercept is most popular anti-TNF with well characterized safety profile in treatment of various auto immune and inflammatory disorders.
  • anti-TNF agent like etanercept can be used for treating, managing, or preventing infectious diseases caused by coronaviruses.
  • the present invention accordingly, provides a composition comprising anti-TNF agent for management of infectious disease caused by coronaviruses.
  • the invention provides a composition comprising anti-TNF agent etanercept for management of infectious disease caused by coronaviruses.
  • the invention provides a composition comprising anti- TNF agent for management of infectious disease COVID-19.
  • the invention provides a composition comprising anti-TNF agent etanercept for management of infectious disease COVID-19.
  • Another embodiment of the invention is to provide composition for management of infectious disease caused by coronaviruses comprising etanercept and other pharmaceutically acceptable excipients.
  • a further embodiment of the invention encompasses methods of treating, managing, or preventing infectious disease caused by coronaviruses which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an anti-TNF agent.
  • Another embodiment of the invention encompasses methods of treating, managing, or preventing infectious disease COVID-19 which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an anti-TNF agent.
  • Yet another embodiment of the invention encompasses methods of treating, managing, or preventing infectious disease caused by coronaviruses which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an anti-TNF agent etanercept.
  • Another embodiment of the invention encompasses methods of treating, managing, or preventing infectious disease COVID-19 which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an anti-TNF agent etanercept.
  • Yet other embodiment of the invention encompasses methods of treating, managing, or preventing infectious disease caused by coronaviruses which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an anti-TNF agent in combination with another therapeutic agent(s).
  • a further embodiment of the invention encompasses methods of treating, managing, or preventing infectious disease COVID-19 which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an anti-TNF agent, etanercept in combination with another therapeutic agent(s).
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent and instructions for administration to a patient in need thereof, for the treatment, management, or prevention of infectious disease caused by coronaviruses.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent and instructions administration of the dosage forms to a patient in need thereof, for the treatment, management, or prevention of infectious disease COVID-19.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent etanercept and instructions for administration to a patient in need thereof, for the treatment, management, or prevention of infectious disease caused by coronavimses.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent etanercept and instructions for administration of the dosage forms to a patient in need thereof, for the treatment, management, or prevention of infectious disease COVID-19.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent and a pharmaceutically acceptable dosage form of another therapeutic agent(s) and instructions for mixing or simultaneous or sequential administration of the dosage forms to a patient in need thereof, for the treatment, management, or prevention of infectious disease caused by coronavimses.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent and a pharmaceutically acceptable dosage form of another therapeutic agent(s) and instructions for mixing or simultaneous or sequential administration of the dosage forms to a patient in need thereof, for the treatment, management, or prevention of COVID-19.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage forms of anti-TNF agent etanercept and a pharmaceutically acceptable dosage form of another therapeutic agent(s) and instructions for mixing or simultaneous or sequential administration of the dosage forms to a patient in need thereof, for the treatment, management, or prevention of infectious disease caused by coronaviruses.
  • the invention provides a kit comprising a pharmaceutically acceptable dosage form of anti-TNF agent etanercept and a pharmaceutically acceptable dosage form of another therapeutic agent(s) and instructions for mixing or simultaneous or sequential administration of the dosage forms to a patient in need thereof, for the treatment, management, or prevention of COVID-19.
  • anti-TNF agent is administered in combination with standard of care protocol used to treat, prevent or manage infectious diseases or disorders caused by coronaviruses.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent etanercept is administered in combination with standard of care protocol used to treat, prevent or manage infectious diseases or disorders caused by coronaviruses.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent is administered in combination with standard of care protocol used to treat, prevent or manage infectious disease COVID-19. Examples of such standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent etanercept is administered in combination with standard of care protocol used to treat, prevent or manage infectious disease COVID-19.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent is administered in combination with another therapeutic agent(s) and standard of care protocol used to treat, prevent or manage infectious diseases or disorders caused by coronaviruses.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent etanercept is administered in combination with another therapeutic agent(s) and standard of care protocol used to treat, prevent or manage infectious diseases or disorders caused by coronaviruses.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent is administered in combination with another therapeutic agent(s) and standard of care protocol used to treat, prevent or manage infectious disease COVID-19.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • anti-TNF agent etanercept is administered in combination with another therapeutic agent(s) and standard of care protocol used to treat, prevent or manage infectious disease COVID-19.
  • standard of care protocol includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood transfusions and other non-drug based therapies.
  • the anti-TNF agent is selected from the group comprising anti-TNF fusion proteins or anti-TNF monoclonal, chimeric, humanized, resurfaced and recombinant antibodies and fragments thereof that are capable of inhibiting TNFa activity, whether fully or partially.
  • the anti-TNF agent is Etanercept.
  • the dose of etanercept is in the range of about 1 to 100 mg and dose range is 0.1 to 20 mg/kg, and preferably is 1- 10 mg/kg.
  • the present invention provides a dosing regimen for administration of anti-TNF agent for the treatment, management, or prevention of infectious diseases or disorders caused by coronaviruses wherein first dose of anti- TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of anti-TNF agent for the treatment, management, or prevention of infectious disease COVID-19 wherein first dose of anti-TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of anti-TNF agent etanercept for the treatment, management, or prevention of infectious diseases or disorders caused by coronaviruses wherein first dose of anti-TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of anti-TNF agent etanercept for the treatment, management, or prevention of infectious disease COVID-19 wherein first dose of anti-TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of infectious diseases or disorders caused by coronaviruses wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of COVID-19 wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of infectious diseases caused by coronaviruses wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer 25 mg to 50 mg of etanercept every 3 to 4 days till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of COVID-19 wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4 with or without combination with other therapeutic agent(s), with an option to administer 25 mg to 50 mg of etanercept every 3 to 4 days till desired outcome is achieved.
  • the present invention provides a dosing regimen for administration of anti-TNF agent for the treatment, management, or prevention of infectious diseases or disorders caused by coronaviruses wherein first dose of anti- TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of anti-TNF agent for the treatment, management, or prevention of infectious disease COVID-19 wherein first dose of anti-TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of anti-TNF agent etanercept for the treatment, management, or prevention of infectious diseases or disorders caused by coronaviruses wherein first dose of anti-TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of anti-TNF agent etanercept for the treatment, management, or prevention of infectious disease COVID-19 wherein first dose of anti-TNF agent is administered on Day 1, and the second dose of anti-TNF agent is administered on Day 4, with an option to administer additional doses till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of infectious diseases or disorders caused by coronaviruses wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer additional doses till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of COVID-19 wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer additional doses till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of infectious diseases caused by coronaviruses wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer 25 mg to 50 mg of etanercept every 3 to 4 days till desired outcome is achieved, in combination with another therapeutic agent(s).
  • the present invention provides a dosing regimen for administration of etanercept for the treatment, management, or prevention of COVID-19 wherein first dose of etanercept 50 mg is administered on Day 1, and the second dose of etanercept 25 mg is administered on Day 4, with an option to administer 25 mg to 50 mg of etanercept every 3 to 4 days till desired outcome is achieved, in combination with another therapeutic agent(s).
  • Coronaviruses are enveloped, positive single stranded large RNA viruses.
  • COVID- 19 is caused by a novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 coronavirus severe acute respiratory syndrome coronavirus 2
  • Accumulating evidence suggests that the severity of COVID-19 is associated with an increased level of inflammatory mediators including cytokines and chemokines like TNF- a, IL-6 and IL-1.
  • TNF is a major component of the cytokine storm. TNF-a levels increase early in the infection and remain elevated throughout the infection. Anti- TNF drugs inhibits the hyper-inflammatory response of the immune system which is a major reason for mortality in Covid-19 patients. Etanercept has shown to decrease clotting biomarker like D-dimer and pro-thrombin fragments seen within 1 h of therapy.
  • Anti-TNF agents alone or in combination with other therapeutic agent(s), are useful in autoimmune and inflammatory conditions and also for treating bacterial, viral, fungal or protozoal infections, and complications resulting therefrom. Accordingly, the present invention relates to administration of anti-TNF agents like etanercept for management of infectious disease caused by coronaviruses.
  • treatment/treating, management/managing, prevention/preventing of infectious disease caused by coronaviruses or COVID-19 comprises prophylaxis and/or treatment, reduction in markers, reduction in lung injury caused by cytokine storm, reduced risk of ARDS, reduction in rate of morbidity and/or mortality caused by low oxygen saturation levels in COVID-19 patients.
  • Treat, treating, or treatment are used broadly in relation to the invention and each such term encompasses, among others, preventing, ameliorating, inhibiting, or curing a deficiency, dysfunction, disease, or other deleterious process, including those that interfere with and/or result from a therapy.
  • administered means that the patient is treated with the agent in an amount and for a time sufficient to induce a sustained improvement in at least one indicator that reflects the severity of the disorder.
  • the degree of improvement is determined based on changes/reduction of biomarker level, signs or symptoms, and determinations may also employ questionnaires that are administered to the patient, such as quality-of-life questionnaires.
  • Various indicators that reflect the extent of the patient's illness may be assessed for determining whether the amount and time of the treatment is sufficient.
  • the baseline value for the chosen indicator or indicators is established by examination of the patient prior to administration of the first dose of the anti-TNF agent with or without another therapeutic agent(s). Preferably, the next examination of the indicators may be done within Day 4, 7 and 14 after administering the first dose.
  • the first dose is administered as soon as practically possible after the disease is diagnosed or symptoms start appearing.
  • Improvement is expected by administering anti-TNF agent with or without another therapeutic agent(s) until the patient manifests an improvement over baseline for the chosen indicator or indicators.
  • compositions comprising a pharmaceutically acceptable excipient and anti-TNF agent.
  • Pharmaceutical compositions disclosed herein typically comprise anti-TNF agent and pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally one or more further pharmaceutically active compounds.
  • composition/dosage form as used herein comprises various pharmaceutically acceptable dosage forms including oral solid as well as liquid dosage forms, such as but not limited to, tablets, soft gelatin capsule, capsules (filled with powders, powders for reconstitution, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, granules, sprinkles microspheres and multi-particulates), sachets (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, granules, sprinkles microspheres and multi-particulates) and sprinkles, liquids, liquid dispersions, suspensions, solutions, emulsions, sprays, spot-on) and the like; parenteral dosage forms such as liquids, liquid dispersions, suspensions, solutions, emulsions, sprays, spot-on) and the like; parenteral dosage forms such as liquids,
  • These dosage forms will usually include one or more pharmaceutically acceptable ingredients or excipients which refers to non- API or inactive substances which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity regulating agents, surfactants, preservatives, flavourings and colorants.
  • pharmaceutically acceptable ingredients or excipients which refers to non- API or inactive substances which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity regulating agents, surfactants, preservatives, flavourings and colorants.
  • compositions comprising aqueous composition of TNF-binding protein comprising a TNF-binding protein, the contents of which are hereby incorporated herein by reference in their entirety.
  • the pharmaceutical composition can be administered orally, intravenously, or through the lungs.
  • subcutaneous route of administration for anti-TNF agent is preferred, whilst oral or parenteral administration of other therapeutic agent(s) is preferred.
  • administration refers to single agent administration or when given in combination it refers to simultaneous administration either by mixing or sequential administration without mixing i.e. in any order, one immediately after the other.
  • Administration of the anti-TNF agent and the other therapeutic agent(s) to a patient can occur simultaneously or sequentially by the same or different routes of administration.
  • active ingredients of the invention may not be administered to a patient at the same time or by the same route of administration.
  • This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
  • kits encompassed by this invention can further comprise additional therapeutic agent(s) comprising but not limited to antivirals, antibiotics, analgesics, corticosteroids, antagonists of inflammatory cytokines, DMARDs and non steroidal anti-inflammatories, biologicals, antimetabolites, analgesics, anticoagulants etc. or a combination thereof.
  • additional therapeutic agent(s) comprising but not limited to antivirals, antibiotics, analgesics, corticosteroids, antagonists of inflammatory cytokines, DMARDs and non steroidal anti-inflammatories, biologicals, antimetabolites, analgesics, anticoagulants etc. or a combination thereof.
  • Kits of the invention can further comprise devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, pre-filled syringes, dual chambered syringe, drip bags, patches, and inhalers. Kits of the invention can further comprise pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
  • Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl
  • Standard of care treatment includes, but are not limited to, supplemental oxygen therapy, vitamins and other minerals, mechanical ventilation, surgery, blood or plasma transfusions and other non-drug based therapies may additionally be administered as per physician’s discretion or as per latest guidelines and protocols by drug regulatory authorities or health agencies.
  • anti-TNF agents comprises any small or large molecule that inhibits TNF.
  • anti-TNF agent is etanercept.
  • anti-TNF agent is administered one time per week to treat the various diseases/disorders disclosed herein, in another embodiment is administered at least two times per week, and in another embodiment is administered at least three times per week.
  • An adult patient is a person who is 18 years of age or older. If injected, the effective amount of anti-TNF agent per adult dose ranges from 1-20 mg/m 2 , and preferably is about 5-12 mg/m 2 .
  • a flat dose may be administered, whose amount may range from 5- 100 mg/dose.
  • Exemplary dose ranges for a flat dose to be administered by subcutaneous injection are 5-25 mg/dose, 25-50 mg/dose and 50-100 mg/dose.
  • the various indications described are treated by administering a preparation acceptable for injection containing anti-TNF agent at 25 mg/dose, or alternatively, containing 50 mg per dose. The 25 mg or 50 mg dose may be administered repeatedly.
  • the dose is appropriately adjusted in accord with standard medical practices.
  • an improvement in a patient's condition will be obtained by injecting a dose of about 25 mg of anti-TNF agent one to three times per week over a period of at least three weeks, or a dose of 50 mg of anti-TNF agent one or two times per week for at least three weeks, though treatment for longer periods may be necessary to induce the desired degree of improvement.
  • the regimen may be continued indefinitely, with adjustments being made to dose and frequency if such are deemed necessary by the patient's physician.
  • anti-TNF agent may be administered in adult or juvenile subject, wherein the dose of the etanercept may range from about 1 to 100 mg and preferred dose range is 0.1 to 20 mg/kg, and preferably is 1-10 mg/kg.
  • a suitable regimen involves the subcutaneous injection of 0.4 mg/kg, up to a maximum dose of 25 mg of etanercept, administered by subcutaneous injection one or more times per week.
  • the dose and the treatment regimen or the duration of treatment may be appropriately carried out by a physician.
  • etanercept at a dose of 50 mg is administered on Day 1
  • the second dose of etanercept 25 mg is administered on Day 4, with an option to administer additional doses till desired outcome is achieved.
  • the additional doses comprise 25 to 50 mg of etanercept every 3 to 4 days till desired outcome is achieved.
  • the invention further includes the administration of anti-TNF agent concurrently with one or more other therapeutic agent(s).
  • “Concurrent administration” encompasses simultaneous or sequential treatment with the components of the combination, as well as regimens in which the therapeutic agents are alternated, or wherein one component is administered long-term and the other(s) are administered intermittently.
  • other therapeutic agents to be administered concurrently include but are not limited to antivirals, antibiotics, analgesics, corticosteroids, antagonists of inflammatory cytokines, DMARDs and non steroidal anti-inflammatories, biologicals, antimetabolites, analgesics, anticoagulants etc. or a combination thereof.
  • a method of treating, managing, or preventing infectious disease caused by coronaviruses which comprises administering to the patient a. first dose of etanercept 50 mg on Day 1 b. second dose of etanercept 25 mg on Day 4 c. single loading dose of remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of 100 mg from Day 2 to Day 5, in a five days cycle.
  • the dose and the treatment regimen or the duration of treatment may be appropriately carried out by a physician.
  • a method of treating, managing, or preventing infectious disease caused by coronaviruses which comprises administering to the patient a. etanercept at a dose of about 50 mg and methotrexate at a dose of about 16 mg on Day 1, followed by a determination of marker level on day 4 and if there is no significant reduction in the markers on day 4, administering etanercept at a dose of 50 mg along with reduced dose of methotrexate which is preferably about 8 mg on Day 5 followed by a determination of marker level on Day 8 and continuing this cycle until there is a significant reduction in the marker level.
  • the dose and the treatment regimen or the duration of treatment may be appropriately carried out by a physician.
  • markers as used in refers to biomarkers comprising but not limited to TNF-alpha, D-dimer, C-reactive protein (CRP), lactic acid dehydrogenase (LDH), IL-6 or serum ferritin.
  • CRP C-reactive protein
  • LDH lactic acid dehydrogenase
  • IL-6 serum ferritin.
  • the biochemical or other methods used to determine the levels of these markers is known to a person skilled in this art.
  • “Desired outcome” as mentioned herein refers to improvement in atleast one of the below mentioned criteria/indicators:
  • Time to clinical recovery Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Uninfected, No clinical or virological evidence of infection; 2) Ambulatory, no limitation of activities; 3) Ambulatory, limitation of activities
  • the invention will be supported by pre-clinical and clinical study in COVID- 19 patients and healthy subjects.
  • a phase II, multi-centre, double blind, randomized, comparative study is designed to evaluate efficacy and safety of composition of etanercept as an add-on therapy to remdesivir in moderate COVID-19 patients.
  • Moderate COVID-19 patients will be categorized as defined by the most recent version of ‘Clinical management protocol: COVID-19' released by Ministry of health and family welfare, Government of India. Patients who meet the eligibility criteria will be randomly assigned to any of the following treatment arms: Treatment Arm 1 (Investigational arm): Etanercept (50/25 mg) + Remdesivir Injection
  • Etanercept dose First dose of Etanercept 50 mg will be administered subcutaneously on Day 1, and the second dose of Etanercept 25 mg will be administered subcutaneously on Day 4.
  • Remdesivir dose* Single loading dose of 200 mg on Day 1 followed by once-daily maintenance doses of 100 mg from Day 2 infused intravenously over 30 to 120 minutes to be given for 5 days.
  • Treatment Arm 2 (Comparator arm): Remdesivir injection + Placebo Remdesivir dose*: Single loading dose of 200 mg on Day 1 followed by once-daily maintenance doses of 100 mg from Day 2 infused intravenously over 30 to 120 minutes to be given for 5 days.
  • Placebo injection will be administered subcutaneously on Day 1 and Day 4 (injection volume will be similar to that of Etanercept in Treatment Arm 1) [*Investigator should follow the most recent COVID-19 clinical management protocol for up-to-date dosing recommendations for Remdesivir]
  • Standard of care treatment SOC such as corticosteroids/anti-virals/anti- biotics/ vitamins etc. will be administered as per investigator’s discretion or institutional protocol or guideline released by Ministry of health and family welfare, Govt of India. Modification in the SOC treatment will be allowed as per investigator’s discretion.
  • assessments may be performed which includes but are not limited to vital signs assessment, physical & systemic examination, 12-lead ECG, RT-PCR, clinical laboratory assessment including biomarkers level, semm/urine pregnancy test in females of childbearing potential only and concomitant medication/ treatment assessment. Patients will be evaluated for Adverse Events (if any). Study Endpoints:
  • Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the WHO Ordinal Scale: 1) Uninfected, No clinical or virological evidence of infection; 2) Ambulatory, no limitation of activities; 3) Ambulatory, limitation of activities]
  • Treatment Arm 1 Investigational arm; 25 patients
  • Etanercept group Lupin’s etanercept (50/25 mg) + Remdesivir Injection.
  • Etanercept dose First dose of etanercept 50 mg was administered subcutaneously on day 1 followed by the second dose of etanercept 25 mg administered subcutaneously on day 4.
  • Remdesivir dose Single loading dose of remdesivir 200 mg was administered on day 1 followed by once-daily maintenance doses of remdesivir 100 mg was infused intravenously over 30 to 120 minutes from day 2 for 5 days.
  • Treatment Arm 2 (Comparator arm; 25 patients) [Placebo group]: Placebo + Remdesivir injection
  • Remdesivir dose Single loading dose of remdesivir 200 mg was administered on day 1 followed by once daily maintenance doses of remdesivir 100 mg was infused intravenously over 30 to 120 minutes from day 2 to be given for 5 days.
  • Standard of care (SOC) treatment such as corticosteroids/anti-viral/antibiotics/ vitamins etc. were administered as per investigator’s discretion.
  • the safety profile was found to be comparable between both the treatment groups with none of the patients discontinuing the study due to adverse events.
  • Etanercept provided higher efficacy compared to placebo in terms of clinical improvement and reduction in inflammatory markers with acceptable safety profile for the treatment of hospitalized COVID-19 patients.
  • the median time to clinical improvement and clinical recovery was 8 days in the etanercept group versus 11 days in the placebo group, indicating faster improvement and earlier recovery by 3 days with etanercept compared to placebo in patients on oxygen support.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la composition pharmaceutique d'un agent anti-facteur de nécrose tumorale (agent anti-TNF), de préférence l'étanercept, pour la gestion de maladies infectieuses causées par des coronavirus. L'invention concerne en outre un procédé d'administration de la quantité thérapeutiquement efficace d'agent anti-TNF seul ou en combinaison avec un ou plusieurs agents thérapeutiques pour la gestion de maladies infectieuses provoquées par des coronavirus. L'invention concerne également des kits comprenant la composition pharmaceutique d'agent anti-TNF seul ou en combinaison avec un ou plusieurs agents thérapeutiques.
PCT/IB2022/055626 2021-06-17 2022-06-17 Composition pharmaceutique d'un agent anti-facteur de nécrose tumorale (anti-tnf) pour la gestion de maladies infectieuses provoquées par des coronavirus Ceased WO2022264097A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121027121 2021-06-17
IN202121027121 2021-06-17

Publications (1)

Publication Number Publication Date
WO2022264097A1 true WO2022264097A1 (fr) 2022-12-22

Family

ID=82595210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/055626 Ceased WO2022264097A1 (fr) 2021-06-17 2022-06-17 Composition pharmaceutique d'un agent anti-facteur de nécrose tumorale (anti-tnf) pour la gestion de maladies infectieuses provoquées par des coronavirus

Country Status (1)

Country Link
WO (1) WO2022264097A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648702B2 (en) 2002-02-27 2010-01-19 Immunex Corporation Stable aqueous formulation of a soluble TNF receptor and arginine
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
WO2014064637A1 (fr) 2012-10-26 2014-05-01 Lupin Limited Composition pharmaceutique stable d'une protéine hybride tnfr:fc

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648702B2 (en) 2002-02-27 2010-01-19 Immunex Corporation Stable aqueous formulation of a soluble TNF receptor and arginine
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
WO2014064637A1 (fr) 2012-10-26 2014-05-01 Lupin Limited Composition pharmaceutique stable d'une protéine hybride tnfr:fc
US20180236030A1 (en) 2012-10-26 2018-08-23 Lupin Limited Stable pharmaceutical composition of tnfr:fc fusion protein
US10058589B2 (en) 2012-10-26 2018-08-28 Lupin Limited Stable pharmaceutical composition of Etanercept in a phosphate citrate buffer with glycine as an anti-aggregating agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEZZIO CRISTINA ET AL: "Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds", GUT MICROBIOTA, vol. 70, no. 3, 1 March 2021 (2021-03-01), UK, pages 623 - 624, XP055966843, ISSN: 0017-5749, Retrieved from the Internet <URL:https://gut.bmj.com/content/gutjnl/70/3/623.full.pdf> DOI: 10.1136/gutjnl-2020-321760 *
HACHEM HILAL ET AL: "Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-[alpha] antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure - PMC", 2 June 2021 (2021-06-02), XP055966930, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183025/?report=printable> [retrieved on 20220930] *
HACHEM HILAL ET AL: "Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF[alpha]-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure", JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, vol. 5, no. 1, 25 June 2021 (2021-06-25), XP055966928, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376916/pdf/S2059866121008050a.pdf> DOI: 10.1017/cts.2021.805 *
STALLMACH ANDREAS ET AL: "Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series", CRITICAL CARE, vol. 24, no. 1, 17 July 2020 (2020-07-17), XP055879484, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366555/pdf/13054_2020_Article_3158.pdf> DOI: 10.1186/s13054-020-03158-0 *

Similar Documents

Publication Publication Date Title
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7671305B2 (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
KR20200105869A (ko) Apl 형 펩타이드를 포함하는 약제학적 조성물
JP7732784B2 (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
US20240392022A1 (en) Treatment of multiple sclerosis with anti-cd40l antibodies
WO2022264097A1 (fr) Composition pharmaceutique d&#39;un agent anti-facteur de nécrose tumorale (anti-tnf) pour la gestion de maladies infectieuses provoquées par des coronavirus
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
JP2025527521A (ja) 急性呼吸不全の治療
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
US20200157208A1 (en) Combination of an antibody that binds to the p19 subunit of human il-23 and a hyaluronidase enzyme
TW202144380A (zh) 用於治療冠狀病毒感染之化合物
JP2023518812A (ja) Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
JP7417339B1 (ja) アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
US20240025991A1 (en) Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
Analgesics Juvenile t Idiopathic Arthritis (JIA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Systemic Juvenile Idiopathic Arthritis (SJIA) see page 281 Acetaminophen for IV Infusion see Pain page 352
Hecht et al. PROTOCOL SYNOPSIS
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
KR20230117106A (ko) 제1 치료 활성 성분으로서의 백신을 제2 활성 성분과 조합하여 사용하여 암을 치료하기 위한 조성물 및 방법
CN121127595A (zh) 利用皮质类固醇治疗的改进型基于腺病毒的基因治疗的组合物和方法
TW202308659A (zh) 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸
US20210030872A1 (en) Method and composition for treating cancer or skin lesion using a vaccine
WO2021207653A1 (fr) Utilisation d&#39;un agoniste de tlr9 dans des procédés de traitement de covid-19

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22743560

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE